DekaBank Deutsche Girozentrale’s Corcept Therapeutics CORT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$288K	Hold	7,360	–	–	﹤0.01%	936
2026 Q1	$294K	Hold	7,360	–	–	﹤0.01%	937
2025 Q4	$191K	Hold	7,360	–	–	﹤0.01%	1153
2025 Q3	$611K	Hold	7,360	–	–	﹤0.01%	952
2025 Q2	$542K	Hold	7,360	–	–	﹤0.01%	969
2025 Q1	$391K	Hold	7,360	–	–	﹤0.01%	1007
2024 Q4	$386K	Hold	7,360	–	–	﹤0.01%	1045
2024 Q3	$319K	Hold	7,360	–	–	﹤0.01%	1087
2024 Q2	$234K	Hold	7,360	–	–	﹤0.01%	1133
2024 Q1	$184K	Hold	7,360	–	–	﹤0.01%	1169
2023 Q4	$241K	Hold	7,360	–	–	﹤0.01%	1167
2023 Q3	$242K	Buy	+7,360	New	+$213K	﹤0.01%	1156

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CORT Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 7,360 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #936.

DekaBank Deutsche Girozentrale first reported a position in CORT in Q3 2023 and has held it in 12 quarters since. The position peaked at $611K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

DekaBank Deutsche Girozentrale held 7,360 shares of Corcept Therapeutics worth $288K as of Q2 2026.
DekaBank Deutsche Girozentrale left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #936 holding.
DekaBank Deutsche Girozentrale first reported a position in Corcept Therapeutics in Q3 2023 and has held it in 12 quarters since.
DekaBank Deutsche Girozentrale's Corcept Therapeutics position peaked at $611K in Q3 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.